Literature DB >> 2998004

Processing of virus-specific glycoproteins of varicella zoster virus.

J Namazue, H Campo-Vera, K Kitamura, T Okuno, K Yamanishi.   

Abstract

Monoclonal antibodies to varicella zoster virus (VZV) glycoproteins were used to study the processing of three glycoproteins with molecular weights of 83K-94K (gp 2), 64K (gp 3), and 55K (gp 5). Immunoprecipitation experiments performed with VZV-infected cells, pulse labeled with [3H]glucosamine in the presence of tunicamycin, suggest that O-linked oligosaccharide is present on the glycoprotein of gp 2. Use of the enzyme endo-beta-N-acetylglucosaminidase H revealed that the fully processed form of gp 3 had high-mannose type and that of gp 5 had only complex type of N-linked oligosaccharides. Experiments with monensin suggest that the precursor form (116K) of gp 3 is cleaved during the processing from Golgi apparatus to cell surface membrane. The extension of O-linked oligosaccharide chain and the complex type of N-linked oligosaccharide chains also occurs during this processing.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2998004      PMCID: PMC7130879          DOI: 10.1016/0042-6822(85)90112-6

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  31 in total

1.  Synchronised transmembrane insertion and glycosylation of a nascent membrane protein.

Authors:  J E Rothman; H F Lodish
Journal:  Nature       Date:  1977-10-27       Impact factor: 49.962

2.  Isolation and polypeptide characterization of varicella-zoster virus.

Authors:  Y Shemer; S Leventon-Kriss; I Sarov
Journal:  Virology       Date:  1980-10-15       Impact factor: 3.616

3.  Vesicular stomatitis virus and sindbis virus glycoprotein transport to the cell surface is inhibited by ionophores.

Authors:  D C Johnson; M J Schlesinger
Journal:  Virology       Date:  1980-06       Impact factor: 3.616

4.  Biogenesis of vaccinia: carbohydrate of the hemagglutinin molecules.

Authors:  H Shida; S Dales
Journal:  Virology       Date:  1981-05       Impact factor: 3.616

5.  Polypeptides of varicella-zoster virus (VZV) and immunological relationship of VZV and herpes simplex virus (HSV).

Authors:  K Shiraki; T Okuno; K Yamanishi; M Takahashi
Journal:  J Gen Virol       Date:  1982-08       Impact factor: 3.891

6.  Tunicamycin, a new antibiotic. I. Isolation and characterization of tunicamycin.

Authors:  A Takatsuki; K Arima; G Tamura
Journal:  J Antibiot (Tokyo)       Date:  1971-04       Impact factor: 2.649

7.  Tunicamycin inhibits glycosylation and multiplication of Sindbis and vesicular stomatitis viruses.

Authors:  R Leavitt; S Schlesinger; S Kornfeld
Journal:  J Virol       Date:  1977-01       Impact factor: 5.103

8.  Suppression of glycoprotein formation of Semliki Forest, influenza, and avian sarcoma virus by tunicamycin.

Authors:  R T Schwarz; J M Rohrschneider; M F Schmidt
Journal:  J Virol       Date:  1976-09       Impact factor: 5.103

9.  O-glycosidic carbohydrate-peptide linkages of Herpes simplex virus glycoproteins.

Authors:  S Olofsson; J Blomberg; E Lycke
Journal:  Arch Virol       Date:  1981       Impact factor: 2.574

10.  Comparative studies of intracellular transport of secretory proteins.

Authors:  A Tartakoff; P Vassalli; M Détraz
Journal:  J Cell Biol       Date:  1978-12       Impact factor: 10.539

View more
  7 in total

1.  Assembly and processing of the disulfide-linked varicella-zoster virus glycoprotein gpII(140).

Authors:  E A Montalvo; C Grose
Journal:  J Virol       Date:  1987-09       Impact factor: 5.103

2.  New common nomenclature for glycoprotein genes of varicella-zoster virus and their glycosylated products.

Authors:  A J Davison; C M Edson; R W Ellis; B Forghani; D Gilden; C Grose; P M Keller; A Vafai; Z Wroblewska; K Yamanishi
Journal:  J Virol       Date:  1986-03       Impact factor: 5.103

3.  Processing of the gp55-116 envelope glycoprotein complex (gB) of human cytomegalovirus.

Authors:  W J Britt; L G Vugler
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

4.  The glycoprotein products of varicella-zoster virus gene 14 and their defective accumulation in a vaccine strain (Oka).

Authors:  P R Kinchington; P Ling; M Pensiero; B Moss; W T Ruyechan; J Hay
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

5.  Varicella-zoster virus glycoprotein oligosaccharides are phosphorylated during posttranslational maturation.

Authors:  C A Gabel; L Dubey; S P Steinberg; D Sherman; M D Gershon; A A Gershon
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

6.  Characterization and immunogenicity of a candidate subunit vaccine against varicella-zoster virus.

Authors:  J Davies; J A Hallworth; P McLeish; S Randall; B A Martin; A Buchan; G R Skinner
Journal:  Med Microbiol Immunol       Date:  1994-05       Impact factor: 3.402

7.  Recognition of similar epitopes on varicella-zoster virus gpI and gpIV by monoclonal antibodies.

Authors:  A Vafai; Z Wroblewska; R Mahalingam; G Cabirac; M Wellish; M Cisco; D Gilden
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.